Clinical Trials Directory
We are doing this study to see if the study drug, dostarlimab, can reduce the recurrence of cancer in people who have had their colon cancer surgically removed.
We are doing this study to understand whether people who receive a lower radiation dose after an interim (the second scan) PET-CT identifies an early treatment response have a similar outcome to those receiving a standard radiation dose. The results of the interim PET-CT scan will be used to guide your radiation dose plan. Depending on the PET-CT results, you will either receive a reduced radiation dose or the standard radiation dose for your cancer.
We are doing this study to find the most effective, safe dose of an experimental drug called petosemtamab (the study drug). We also want to know how well it works compared to the standard treatments used for metastatic/recurrent head and neck squamous cell carcinoma (HNSCC).
We are doing this study to find the most effective, safe dose of an experimental drug called PF-0793440 (the study drug). We want to know how well it works on its own and in combination with other drugs for the treatment of different cancers in people who have KRAS mutation(s).
We are doing this study to find out if an experimental drug called navtemadlin (the study drug) is a safe and effective option for people with myelofibrosis (MF). We want to know how well it works when it is combined with ruxolitinib for people who did not get the desired results from ruxolitinib on its own.
We are doing this study to find the most effective, safe dose of an experimental drug called CLN-049 (the study drug) for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
We are doing this study to find out if an experimental drug called SRG-514 (the study drug) is a safe and effective option for breast cancer patients. We want to know if it can reduce the inflammation caused by surgery and allow your body to better heal itself and prevent tumor recurrence. We will also be trying to figure out the best dose of the drug to use.
We are doing this study to find the most effective, safe dose of an experimental drug called V940 (the study drug) when it is given with pembrolizumab to people who have had surgery to remove their bladder, kidney, or other organs for muscle-invasive urothelial carcinoma. We want to know how well this combination works compared to taking pembrolizumab on its own.